Altimmune, Inc. License Agreements
9 Contracts & Agreements
- Amendment No. 6 to the Second Restated License Agreement, effective as of January 22, 2021, between Janssen Vaccines & Prevention B.V. (formerly Crucell Holland B.V.) and... (Filed With SEC on May 17, 2021)
- Amendment No. 5 to Second Restated License Agreement, effective as of October 22, 2020, between Janssen Vaccines & Prevention B.V. (formerly Crucell Holland B.V.) and Altimmune,... (Filed With SEC on February 25, 2021)
- Amendment No. 4 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of July 28, 2020 (Filed With SEC on November 9, 2020)
- Amendment No. 3 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of April 2, 2020 (Filed With SEC on August 11, 2020)
- Amendment No. 2 to the Second Restated License Agreement, by and among Altimmune, Inc. and Janssen Vaccines & Prevention B.V., dated as of September 20, 2016 (Filed With SEC on August 11, 2020)
- Amended and Restated License Agreement, dated July 12, 2019, by and between Mederis Diabetes, LLC and Spitfire Pharma, Inc (Filed With SEC on November 13, 2019)
- AMENDMENT NO. 1 TO SECONDRESTATED LICENSE AGREEMENT (Filed With SEC on August 14, 2017)
- First Amendment to Amended and Restated Exclusive License Agreement (Filed With SEC on August 14, 2017)
- AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (Filed With SEC on August 14, 2017)
